SUVmax after (18)fluoro-deoxyglucose positron emission tomography/computed tomography: A tool to define treatment strategies in pancreatic cancer

I Pergolini, S Crippa, Matteo Salgarello, G Belfiori, S Partelli, G Ruffo, A Pucci, Giuseppe Zamboni, M Falconi

Research output: Contribution to journalArticle


Background: (18)fluoro-deoxyglucose positron emission tomography/computed tomography (18FDG-PET/CT) might be a useful tool in the management of pancreatic ductal adenocarcinoma (PDAC). Aims: The aim of this study was to analyze maximum standard uptake value (SUVmax) after 18FDG-PET/CT as predictor of survival outcomes and method to determine treatment strategies. Methods: A consecutive series of patients who underwent preoperative 18FDG-PET/CT and subsequent resection for PDAC were retrospectively reviewed. Patients who underwent neoadjuvant chemotherapy were excluded. Results: 46 patients were included in the analysis. Median follow-up was 27 months (4-67). Patients who recurred within 12 months showed a significantly higher preoperative median SUVmax (8.1 vs 6.1, p = 0.039). Receiver operating characteristics (ROC) curves for disease-free survival (DFS) and disease-specific survival (DSS) identified SUVmax of 6.0 as optimal cut-off. Multivariate analysis showed that SUVmax ≥ 6.0 was an independent predictor of poor DFS (HR 2.288, p = 0.024) and DSS (HR 4.875, p. <. 0.001). The combination of SUVmax ≥6.0 with CA19.9 ≥200. U/ml was significantly associated with survival outcomes in comparison to patients without concordantly elevated values. Conclusion: SUVmax ≥6.0 is an independent predictor of DFS and DSS in resected PDAC. 18FDG-PET/CT might be considered in the preoperative evaluation of patients with pancreatic cancer. © 2017 Editrice Gastroenterologica Italiana S.r.l.
Original languageEnglish
Pages (from-to)84-90
Number of pages7
JournalDigestive and Liver Disease
Issue number1
Publication statusPublished - 2018


Cite this